PTIX Form 3: Barrett Evans reports 16,233 common, 1,000 Series D
Protagenic Therapeutics (PTIX): Barrett Evans filed a Form 3 initial statement of beneficial ownership effective 05/15/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Protagenic Therapeutics (PTIX): Barrett Evans filed a Form 3 initial statement of beneficial ownership effective 05/15/2025. He is identified as a Director, 10% Owner, and ex CEO.
- Common Stock: 16,233 shares, indirect via EMC2 Capital LLC.
- Preferred Series C: 787 shares, indirect via EMC2 Capital LLC.
- Preferred Series C‑1: 131,034 shares, indirect via EMC2 Capital LLC.
- Preferred Series D: 1,000 shares direct; 4,498 shares indirect via EMC2 Capital LLC; 1,000 shares indirect via Mammoth Crest Capital LLC.
The filing notes Mr. Evans was the CEO and is a Director of PTIX.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock | -- | -- | -- |
| Holding | Preferred Stock Series C | -- | -- | -- |
| Holding | Preferred Stock Series C-1 | -- | -- | -- |
| Holding | Preferred Stock Series D | -- | -- | -- |
| Holding | Preferred Stock Series D | -- | -- | -- |
| Holding | Preferred Stock Series D | -- | -- | -- |
Footnotes (1)
- F1. Mr. Evans was the CEO and is a Director of PTIX
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did PTIX disclose in this Form 3 filing?
What is Barrett Evans’s relationship to PTIX (PTIX)?
Are any PTIX holdings reported as direct ownership?
What is the event date for this PTIX Form 3?
AI-generated analysis. How Rhea-AI works. Not financial advice.